Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat ...

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago. These ...

The market expects Inovio Pharmaceuticals (INO) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...

This was the stock's third consecutive day of losses.

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Inovio Pharmaceuticals (INO). The reason why I want to go over this biotech next is because it ...

It's been an up-and-down year for Inovio Pharmaceuticals (NASDAQ: INO). Shares were up nearly 70% in June before surrendering the gains. The clinical-stage biotech announced its third-quarter results ...

The stock's fall snapped a two-day winning streak.